Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Changzhou Pharmaceutical Co., Ltd., a subsidiary of the company, received the “Drug Registration Certificate” (certificate numbers: 2026S03098, 2026S03096, 2026S03097) issued by the State Drug Administration for lucotinib tablets, and the drug was approved for production.

Lucotinib phosphate tablets are suitable for: 1. Myelofibrosis. It is used in adult patients with moderate or high risk primary myelofibrosis (PMF) (also known as chronic idiopathic myelofibrosis), myelofibrosis secondary to polycythemia vera (PPV-MF), or bone marrow fibrosis (PET-MF) secondary to primary thrombocytosis to treat disease-related splenomegaly or disease-related symptoms; 2. Graft versus host disease. It is used to treat patients with acute graft-versus-host disease (acute GVHD) or chronic graft-versus-host disease (chronic GVHD) age 12 years and older who have inadequate response to glucocorticoids or other systemic treatments. The drug was jointly developed by Incyte and Novartis and marketed in the US in November 2011.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.